null

null

null

null

null

null

null

null

null

null

null

null

null

null

-6.11x Total Debt / Equity (Negative equity)

Low direct sensitivity; minimal long-term debt, but higher rates increase cost of equity financing critical for cash-burn-stage medical device company

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Chinese manufacturing of orthodontic appliance components; 2) Taiwanese precision dental material suppliers for proprietary DNA appliance fabrication

Limited international revenue; primary markets are US-based; nascent EU and Australia exposure creates modest EUR and AUD devaluation risk

~85% US revenue; EUR exposure via European dental partnerships and AUD via Australian distributors; combined FX risk under 15% of revenue

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on BioTechUSA and select FDA-cleared lab partners for DNA appliance fabrication; single-lab concentration likely exceeds 30% of device input cost

Medical device/dental technology company; cloud disruption would impair CRM and telehealth tools but core appliance delivery is physical, not cloud-native

Training and certification revenue stream for dentists; 30-day cloud termination would disrupt e-learning platform but classroom delivery could substitute short-term

Moderate API coupling risk; Salesforce CRM and LMS platform integrations exist but are replaceable; no deeply proprietary API dependencies identified

Low Howey risk; revenue derived from medical device sales and dentist training fees—clearly commercial transactions, not investment contracts

Very High

Moderate HIPAA exposure as primary concern; GDPR risk low given minimal EU patient data; CCPA applicability modest given B2B dentist-facing model

Low antitrust risk; niche oral appliance market with numerous competitors; market share under 5% nationally in sleep apnea/orthodontic device segment

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional (~80%); recurring elements include dentist subscription training/certification fees (~20%); multi-year contracts minimal

Device-per-case revenue model; dentists pay per appliance case submitted; supplemented by training program fees and annual membership/certification subscriptions

Per-case device pricing ($1,500–$3,000 per appliance) with fixed training fees; limited pricing power under insurance reimbursement pressure and lab cost inflation

Low-to-moderate; dental device pricing constrained by insurance reimbursement schedules, competitor alternatives, and dentist price sensitivity; 3/10

60.4% Gross Margin (Premium (>60%))

Moderate free-rider risk; dentists trained on Vivos methodology may source similar appliances from competing labs post-certification; protocol IP not fully locked

Headcount-sublinear for device revenue (fab outsourced) but headcount-linear for training/sales expansion; doubling revenue requires ~60–70% headcount increase

Marginal cost of device revenue growth is low (outsourced manufacturing); marginal cost of dentist network expansion is high (field sales, clinical educators)

Not a franchise model; however, certified dentist network compliance with Vivos protocols is difficult to enforce post-training, creating protocol drift risk

At 10x scale (~10,000 active dentists), CAC likely compresses via peer referral but field sales cost remains high; estimated CAC $3,000–$5,000 per dentist

Weak network effects; larger dentist network improves brand credibility but does not structurally increase product value for existing users; not self-reinforcing

-84.4% Return on Assets (Negative equity)

Low recession resistance; elective dental and sleep apnea appliance spending defers during downturns; classified as discretionary healthcare, Tier 3 resilience

General dentists and orthodontists in the US seeking to expand into sleep apnea and craniofacial treatment; estimated 3,000–5,000 active certified providers

Pediatric dentists and ENT-adjacent dental specialists adopting early intervention protocols; smaller segment with higher clinical complexity and longer sales cycle

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

13.4% CapEx / Revenue (Moderate-CapEx)

0001716166

VVOS